Letters to Policy Makers
Rheumatology advocacy involves several branches of government and various agencies. ACR advocates to Congress, federal agencies, and others by writing or signing on to various policy letters.
2024 Federal Advocacy Letters
ONC: Clinical Registries – ACR Supports Updates to USCDI+ – 10/15/2024
ONC: ACR Supports ONC's Proposed Framework for Health IT Regulation through 2030 – 5/28/2024
Congress: Laboratory Developed Tests (LDTs) Should be Easy to Access and Safe to Use – 4/3/2024
ACR Responds to FDA Laboratory Developed Tests Proposed Rule – 12/4/2023
ACR Joins Broad Coalition Letter in Support of CMS Implementing G2211 – 9/7/2023
ACR Leads Cognitive Specialties Coalition Letter in Support of CMS Implementing G2211 – 9/6/2023
ACR Joins Safe Step Coalition in Thanking House Leaders of the Safe Step Act – 7/11/2023
ACR Letter Addressing the High Prices of Drugs Covered under Medicare Part B – 5/5/2023
ACR Comments on IRA Drug Price Negotiation Guidance – 4/14/2023